Introduction: Air trapping because of chronic obstructive pulmonary disease (COPD) leads to a reduction in inspiratory capacity/total lung capacity (IC/TLC) ratio. We hypothesize that COPD patients with a low IC/TLC ratio suffer more frequent COPD exacerbations.
Methods: Retrospective cohort study of patients with COPD, aged 30 years or older with forced expiratory volume in 1 second <70% predicted and forced expiratory volume in 1 second/forced expiratory volume (FEV1/FVC) ratio <70% treated in our ambulatory care clinic for 3 years (2003-2006). Patients were divided in 2 groups, either IC/TLC ratio less than or greater than 25%.
Results: Charts of 350 patients with COPD were reviewed. Of the 77 patients who met inclusion criteria, 28 patients (20 women and 8 men) had IC/TLC ratio <25% (low group) and 49 patients (25 women and 24 men) had IC/TLC ratio >25% (high group). Average number of exacerbations per person in the low group was 3.5 (0-10), significantly higher than in the high group, which was 2.2 (0-10; P = 0.01). Visits for COPD exacerbations were analyzed based on treatment site namely, office, emergency room (ER), and hospital. The per person office visits were 1.96 (0-10) in the low group and 0.80 (0-3) in the high group (P = 0.002). ER visits were similar, 0.57 (0-3) in the low group and 0.38 (0-3) in the high group (P = 0.15), as were hospital visits, 0.96 (0-8) in the low group and 1.06 (0-5) in the high group (P = 0.81).
Conclusion: COPD patients in the low group experienced significantly more unscheduled office visits because of exacerbations, suggesting they need early identification and closely monitored therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MAJ.0b013e3181d6578c | DOI Listing |
Cell Rep Med
January 2025
Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei New ΙΙ Han Institute for Integrative Lung Cancer Research, Yonsei University of Medicine, Seoul, Republic of Korea. Electronic address:
Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) pose therapeutic challenge due to limited response to EGFR tyrosine kinase inhibitors (TKIs). This study presents preclinical evidence and mechanistic insights into the combination of lazertinib, a third-generation EGFR-TKI; and amivantamab, an EGFR-MET bispecific antibody, for treating NSCLC with uncommon EGFR mutations. The lazertinib-amivantamab combination demonstrates significant antitumor activity in patient-derived models with uncommon EGFR mutations either before treatment or after progressing on EGFR-TKIs.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, University of Eastern Piedmont 28100 Novara, Italy; Center for Translational Research on Autoimmune and Allergic Diseases, University of Eastern Piedmont 28100 Novara, Italy. Electronic address:
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to widespread post-acute sequelae of COVID-19 (PASC), affecting multiple body systems. Despite its prevalence, PASC's pathogenesis remains unclear, with hypotheses suggesting viral persistence, immune activation, and autoimmune responses among the pathogenetic mechanism. This study aimed to evaluate T cell memory response in PASC patients, one year post-hospital discharge and correlate it with clinical parameters to identify a potential PASC-associated fingerprint.
View Article and Find Full Text PDFFASEB J
January 2025
Stem Cell and Biotherapy Technology Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease characterized by abnormal activation of myofibroblasts and pathological remodeling of the extracellular matrix, with a poor prognosis and limited treatment options. Lung transplantation is currently the only approach that can extend the life expectancy of patients; however, its applicability is severely restricted due to donor shortages and patient-specific limitations. Therefore, the search for novel therapeutic strategies is imperative.
View Article and Find Full Text PDFInterstitial lung disease (ILD) can lead to pulmonary hypertension (ILD-PH), worsening prognosis and increasing mortality. Diagnosing ILD-PH is challenging due to the limitations of imaging methods. Right heart catheterization (RHC) is the gold standard for diagnosing PH but is limited to ILD patients considered for lung transplantation.
View Article and Find Full Text PDFEur Cardiol
December 2024
Department of Respiratory Medicine, King George's Medical University Lucknow, Uttar Pradesh, India.
Pulmonary arterial hypertension (PAH) is a long-term condition characterised by increased resistance to blood flow in the pulmonary circulation. The disease has a progressive course and is associated with a poor prognosis. Without treatment, PAH is associated with mortality in <3 years.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!